Activities of Atazanavir (BMS-232632) against a Large Panel of Human Immunodeficiency Virus Type 1 Clinical Isolates Resistant to One or More Approved Protease Inhibitors

To evaluate the cross-resistance profile of the human immunodeficiency virus type 1 protease inhibitor (PI) atazanavir (BMS-232632), a panel of 551 clinical isolates exhibiting a wide array of PI resistance profiles and a variety of genotypic patterns were assayed for susceptibility to atazanavir an...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Colonno, Richard J., Thiry, Alexandra, Limoli, Kay, Parkin, Neil
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society for Microbiology 2003
Materias:
Antiviral Agents
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC152527/
https://ncbi.nlm.nih.gov/pubmed/12654666
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.47.4.1324-1333.2003
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares